The law firm of Kirby McInerney LLP is investigating potential claims against Helius Medical Technologies, Inc. (Helius or the Company) (NASDAQ: HSDT). This investigation concerns whether Helius has violated federal securities laws and/or engaged in other unlawful business practices.
On April 10, 2019, Helius announced that the U.S. Food and Drug Administration (FDA) had declined the Companys request for De Novo classification and 510(k) clearance of the Companys Portable Neuromodulation Stimulator (PoNS„¢) device.
On this news, shares of Helius fell $4.11, approximately 66.2%, to close at $2.10 on April 10, 2019.
If you acquired Helius securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, and whistleblower litigation. The firms efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLPs website: www.kmllp.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.